Endothelin receptor-A is required for the recruitment of antitumor T cells and modulates chemotherapy induction of cancer stem cells

References

• Bhalla A, Haque S, Taylor I, Winslet M, Loizidou M. Endothelin receptor antagonism and cancer. Eur J Clin Invest 2009; 39:Suppl 2 74 - 7; http://dx.doi.org/10.1111/j.1365-2362.2009.02123.x; PMID: 19335749
   PubMedGoogle Scholar
• Grimshaw MJ. Endothelins in breast tumour cell invasion. Cancer Lett 2005; 222:129 - 38; http://dx.doi.org/10.1016/j.canlet.2004.08.029; PMID: 15863261
   PubMed Web of Science ®Google Scholar
• Hagemann T, Binder C, Binder L, Pukrop T, Trümper L, Grimshaw MJ. Expression of endothelins and their receptors promotes an invasive phenotype of breast tumor cells but is insufficient to induce invasion in benign cells. DNA Cell Biol 2005; 24:766 - 76; http://dx.doi.org/10.1089/dna.2005.24.766; PMID: 16274297
   PubMed Web of Science ®Google Scholar
• Bagnato A, Natali PG. Endothelin receptors as novel targets in tumor therapy. J Transl Med 2004; 2:16; http://dx.doi.org/10.1186/1479-5876-2-16; PMID: 15165288
   PubMedGoogle Scholar
• Nelson J, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003; 3:110 - 6; http://dx.doi.org/10.1038/nrc990; PMID: 12563310
   PubMed Web of Science ®Google Scholar
• Bagnato A, Salani D, Di Castro V, Wu-Wong JR, Tecce R, Nicotra MR, et al. Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth. Cancer Res 1999; 59:720 - 7; PMID: 9973223
   PubMed Web of Science ®Google Scholar
• Kojima K, Nihei Z. Expression of endothelin-1 immunoreactivity in breast cancer. Surg Oncol 1995; 4:309 - 15; http://dx.doi.org/10.1016/S0960-7404(10)80043-X; PMID: 8809953
   PubMed Web of Science ®Google Scholar
• Nakamuta M, Ohashi M, Tabata S, Tanabe Y, Goto K, Naruse M, et al. High plasma concentrations of endothelin-like immunoreactivities in patients with hepatocellular carcinoma. Am J Gastroenterol 1993; 88:248 - 52; PMID: 8380950
   PubMed Web of Science ®Google Scholar
• Shankar A, Loizidou M, Aliev G, Fredericks S, Holt D, Boulos PB, et al. Raised endothelin 1 levels in patients with colorectal liver metastases. Br J Surg 1998; 85:502 - 6; http://dx.doi.org/10.1046/j.1365-2168.1998.00660.x; PMID: 9607532
   PubMed Web of Science ®Google Scholar
• Bagnato A, Spinella F, Rosanò L. Emerging role of the endothelin axis in ovarian tumor progression. Endocr Relat Cancer 2005; 12:761 - 72; http://dx.doi.org/10.1677/erc.1.01077; PMID: 16322321
   PubMed Web of Science ®Google Scholar
• Salani D, Di Castro V, Nicotra MR, Rosanò L, Tecce R, Venuti A, et al. Role of endothelin-1 in neovascularization of ovarian carcinoma. Am J Pathol 2000; 157:1537 - 47; http://dx.doi.org/10.1016/S0002-9440(10)64791-8; PMID: 11073813
   PubMed Web of Science ®Google Scholar
• Morbidelli L, Orlando C, Maggi CA, Ledda F, Ziche M. Proliferation and migration of endothelial cells is promoted by endothelins via activation of ETB receptors. Am J Physiol 1995; 269:H686 - 95; PMID: 7653633
   PubMed Web of Science ®Google Scholar
• Rosanò L, Salani D, Di Castro V, Spinella F, Natali PG, Bagnato A. Endothelin-1 promotes proteolytic activity of ovarian carcinoma. Clin Sci (Lond) 2002; 103:Suppl 48 306S - 9S; PMID: 12193110
   PubMed Web of Science ®Google Scholar
• Salani D, Taraboletti G, Rosanò L, Di Castro V, Borsotti P, Giavazzi R, et al. Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol 2000; 157:1703 - 11; http://dx.doi.org/10.1016/S0002-9440(10)64807-9; PMID: 11073829
   PubMed Web of Science ®Google Scholar
• Hoosein MM, Dashwood MR, Dawas K, Ali HM, Grant K, Savage F, et al. Altered endothelin receptor subtypes in colorectal cancer. Eur J Gastroenterol Hepatol 2007; 19:775 - 82; http://dx.doi.org/10.1097/MEG.0b013e3282c563de; PMID: 17700263
   PubMed Web of Science ®Google Scholar
• Carducci MA, Jimeno A. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res 2006; 12:6296s - 300s; http://dx.doi.org/10.1158/1078-0432.CCR-06-0929; PMID: 17062717
   PubMed Web of Science ®Google Scholar
• Rosanò L, Cianfrocca R, Spinella F, Di Castro V, Nicotra MR, Lucidi A, et al. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. Clin Cancer Res 2011; 17:2350 - 60; http://dx.doi.org/10.1158/1078-0432.CCR-10-2325; PMID: 21220476
   PubMed Web of Science ®Google Scholar
• Kim SJ, Kim JS, Kim SW, Brantley E, Yun SJ, He J, et al. Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human ovarian cancer. Neoplasia 2011; 13:167 - 79; PMID: 21403842
   PubMed Web of Science ®Google Scholar
• James ND, Caty A, Payne H, Borre M, Zonnenberg BA, Beuzeboc P, et al. Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial. BJU Int 2010; 106:966 - 73; http://dx.doi.org/10.1111/j.1464-410X.2010.09638.x; PMID: 20840318
   PubMed Web of Science ®Google Scholar
• Witteveen PO, van der Mijn KJ, Los M, Kronemeijer RH, Groenewegen G, Voest EE. Phase 1/2 study of atrasentan combined with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer. Neoplasia 2010; 12:941 - 5; PMID: 21076619
   PubMed Web of Science ®Google Scholar
• Ziche M, Morbidelli L, Donnini S, Ledda F. ETB receptors promote proliferation and migration of endothelial cells. J Cardiovasc Pharmacol 1995; 26:Suppl 3 S284 - 6; PMID: 8587389
   PubMedGoogle Scholar
• Buckanovich RJ, Facciabene A, Kim S, Benencia F, Sasaroli D, Balint K, et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med 2008; 14:28 - 36; http://dx.doi.org/10.1038/nm1699; PMID: 18157142
   PubMed Web of Science ®Google Scholar
• Sidharta PN, van Giersbergen PL, Halabi A, Dingemanse J. Macitentan: entry-into-humans study with a new endothelin receptor antagonist. Eur J Clin Pharmacol 2011; 67:977 - 84; http://dx.doi.org/10.1007/s00228-011-1043-2; PMID: 21541781
   PubMed Web of Science ®Google Scholar
• Raja SG. Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis. Curr Opin Investig Drugs 2010; 11:1066 - 73; PMID: 20730702
   PubMed Web of Science ®Google Scholar
• Silva IA, Bai S, McLean K, Yang K, Griffith K, Thomas D, et al. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res 2011; 71:3991 - 4001; http://dx.doi.org/10.1158/0008-5472.CAN-10-3175; PMID: 21498635
   PubMed Web of Science ®Google Scholar
• Winer I, Wang S, Lee YE, Fan W, Gong Y, Burgos-Ojeda D, et al. F3-targeted cisplatin-hydrogel nanoparticles as an effective therapeutic that targets both murine and human ovarian tumor endothelial cells in vivo. Cancer Res 2010; 70:8674 - 83; http://dx.doi.org/10.1158/0008-5472.CAN-10-1917; PMID: 20959470
   PubMed Web of Science ®Google Scholar
• Pulaski HL, Spahlinger G, Silva IA, McLean K, Kueck AS, Reynolds RK, et al. Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. J Transl Med 2009; 7:49; http://dx.doi.org/10.1186/1479-5876-7-49; PMID: 19545375
   PubMed Web of Science ®Google Scholar
• Zhang L, Yang N, Garcia JR, Mohamed A, Benencia F, Rubin SC, et al. Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. Am J Pathol 2002; 161:2295 - 309; http://dx.doi.org/10.1016/S0002-9440(10)64505-1; PMID: 12466143
   PubMed Web of Science ®Google Scholar
• Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133:704 - 15; http://dx.doi.org/10.1016/j.cell.2008.03.027; PMID: 18485877
   PubMed Web of Science ®Google Scholar
• Burgos-Ojeda D, Rueda BR, Buckanovich RJ. Ovarian cancer stem cell markers: prognostic and therapeutic implications. Cancer Lett 2012; 322:1 - 7; http://dx.doi.org/10.1016/j.canlet.2012.02.002; PMID: 22334034
   PubMed Web of Science ®Google Scholar
• Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T, et al. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 2009; 28:209 - 18; http://dx.doi.org/10.1038/onc.2008.374; PMID: 18836486
   PubMed Web of Science ®Google Scholar
• Landen CN Jr., Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, et al. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther 2010; 9:3186 - 99; http://dx.doi.org/10.1158/1535-7163.MCT-10-0563; PMID: 20889728
   PubMed Web of Science ®Google Scholar
• Sampaio AL, Rae GA, Henriques MM. Role of endothelins on lymphocyte accumulation in allergic pleurisy. J Leukoc Biol 2000; 67:189 - 95; PMID: 10670579
   PubMed Web of Science ®Google Scholar
• Wang HH, Hsieh HL, Yang CM. Nitric oxide production by endothelin-1 enhances astrocytic migration via the tyrosine nitration of matrix metalloproteinase-9. J Cell Physiol 2010; PMID: 21660948
   PubMed Web of Science ®Google Scholar
• Ma HJ, Zhu WY, Wang DG, Yue XZ, Li CR. Endothelin-1 combined with extracellular matrix proteins promotes the adhesion and chemotaxis of amelanotic melanocytes from human hair follicles in vitro. Cell Biol Int 2006; 30:999 - 1006; http://dx.doi.org/10.1016/j.cellbi.2006.07.007; PMID: 16990029
   PubMed Web of Science ®Google Scholar
• Masamune A, Satoh M, Kikuta K, Suzuki N, Shimosegawa T. Endothelin-1 stimulates contraction and migration of rat pancreatic stellate cells. World J Gastroenterol 2005; 11:6144 - 51; PMID: 16273641
   PubMed Web of Science ®Google Scholar
• Kitamura A, Kagami S, Urushihara M, Kondo S, Yoshizumi M, Tamaki T, et al. Endothelin-1 is a potent stimulator of alpha1beta1 integrin-mediated collagen matrix remodeling by rat mesangial cells. Biochem Biophys Res Commun 2002; 299:555 - 61; http://dx.doi.org/10.1016/S0006-291X(02)02693-1; PMID: 12459174
   PubMed Web of Science ®Google Scholar
• Guruli G, Pflug BR, Pecher S, Makarenkova V, Shurin MR, Nelson JB. Function and survival of dendritic cells depend on endothelin-1 and endothelin receptor autocrine loops. Blood 2004; 104:2107 - 15; http://dx.doi.org/10.1182/blood-2003-10-3559; PMID: 15213100
   PubMed Web of Science ®Google Scholar
• Chang B, Liu G, Xue F, Rosen DG, Xiao L, Wang X, et al. ALDH1 expression correlates with favorable prognosis in ovarian cancers. Mod Pathol 2009; 22:817 - 23; PMID: 19329942
   PubMed Web of Science ®Google Scholar
• De Angeli S, Del Pup L, Febas E, Conconi MT, Tommasini M, Di Liddo R, et al. Adrenomedullin and endothelin-1 stimulate in vitro expansion of cord blood hematopoietic stem cells. Int J Mol Med 2004; 14:1083 - 6; PMID: 15547678
   PubMed Web of Science ®Google Scholar
• Steg AD, Bevis KS, Katre AA, Ziebarth A, Alvarez RD, Zhang K, et al. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res 2011; PMID: 22142828
   PubMed Web of Science ®Google Scholar
• Carducci MA, Saad F, Abrahamsson PA, Dearnaley DP, Schulman CC, North SA, et al, Atrasentan Phase III Study Group Institutions. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007; 110:1959 - 66; http://dx.doi.org/10.1002/cncr.22996; PMID: 17886253
   PubMed Web of Science ®Google Scholar
• Nelson JB, Love W, Chin JL, Saad F, Schulman CC, Sleep DJ, et al, Atrasentan Phase 3 Study Group. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 2008; 113:2478 - 87; http://dx.doi.org/10.1002/cncr.23864; PMID: 18785254
   PubMed Web of Science ®Google Scholar
• Witteveen PO, van der Mijn KJ, Los M, Kronemeijer RH, Groenewegen G, Voest EE. Phase 1/2 study of atrasentan combined with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer. Neoplasia 2010; 12:941 - 5; PMID: 21076619
   PubMed Web of Science ®Google Scholar
• Kim S-J, Kim JS, Kim SW, Yun SJ, He J, Brantley E, et al. Antivascular therapy for multidrug-resistant ovarian tumors by macitentan, a dual endothelin receptor antagonist. Transl Oncol 2012; 5:39 - 47; PMID: 22348175
   PubMed Web of Science ®Google Scholar
• Rosanò L, Cianfrocca R, Spinella F, Di Castro V, Nicotra MR, Lucidi A, et al. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. Clin Cancer Res 2011; 17:2350 - 60; http://dx.doi.org/10.1158/1078-0432.CCR-10-2325; PMID: 21220476
   PubMed Web of Science ®Google Scholar